Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1‐deficient breast cancer cells to PARP1 inhibition

Lipase-Triggered Water-Responsive “Pandora's Box” for Cancer Therapy: Toward Induced Neighboring Effect and Enhanced Drug Penetration

(2018) Cheng Wang et al.   ADVANCED MATERIALS

Facile preparation of biocompatible nanostructured lipid carrier with ultra-small size as a tumor-penetration delivery system

(2018) Xin Zhao et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy

(2018) Dongyang Tang et al.   RSC Advances

Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin

(2018) Hui Xiong et al.   Biomaterials Science

Primary tumor and pre-metastatic niches co-targeting “peptides-lego” hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment

(2018) Hui Xiong et al.   Biomaterials Science

DOX Loaded Aggregation-induced Emission Active Polymeric Nanoparticles as a Fluorescence Resonance Energy Transfer Traceable Drug Delivery System for Self-indicating Cancer Therapy

(2018) Cheng Wang et al.   Acta Biomaterialia

BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness

(2017) Pawel Domagala et al.   INTERNATIONAL JOURNAL OF CANCER

Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

(2017) Benjamin Blasco et al.   NATURE MEDICINE

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

(2016) Sherry X. Yang et al.   CANCER TREATMENT REVIEWS

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

(2016) Thomas A Mace et al.   GUT

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

(2016) Martine Piccart-Gebhart et al.   JOURNAL OF CLINICAL ONCOLOGY

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers

(2016) Emma Nolan et al.   NATURE MEDICINE

Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway

(2015) J Chen et al.   ONCOGENE

miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway

(2015) Ismael Riquelme et al.   CELLULAR ONCOLOGY

Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition

(2012) Siker Kimbung et al.   CANCER LETTERS

Targeting the Akt/mTOR pathway in Brca1-deficient cancers

(2011) T Xiang et al.   ONCOGENE

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective

(2009) Shahneen K. Sandhu et al.   EUROPEAN JOURNAL OF CANCER

Pharmacotherapy of triple-negative breast cancer

(2009) Cagatay Arslan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Negative Regulation of AKT Activation by BRCA1

(2008) T. Xiang et al.   CANCER RESEARCH

Widespread changes in protein synthesis induced by microRNAs

(2008) Matthias Selbach et al.   NATURE